Who Owns Menicon?

Menicon publishes corporate information about its operations through its website but does not publish a comprehensive standalone sustainability report comparable to the publicly traded major manufacturers. The company's manufacturing operations in Japan and Singapore are subject to respective national environmental regulations.

Menicon has not announced a formal net-zero emissions target, science-based emissions reduction commitment, or third-party carbon neutral certification as of August 2026. The company's environmental disclosures focus on manufacturing operations and product design rather than comprehensive carbon accounting.

Contact lens waste is an industry-wide concern. Menicon has not announced a dedicated post-consumer recycling program for its contact lenses comparable to Bausch and Lomb's ONE by ONE program or CooperVision's plastic neutrality initiative. The Miru 1day flat pack design uses less packaging material than traditional blister packs, which the company references as a packaging efficiency benefit, though this has not been independently certified.

Menicon's expansion into veterinary medical and life care businesses reflects a diversification strategy that extends beyond contact lenses. The company's ethical and regulatory compliance is governed by Japanese pharmaceutical and medical device regulations, as well as FDA and equivalent regulations in export markets.

Menicon's founder, Kyoichi Tanaka, is recognized for developing the first corneal contact lens in Japan in 1951. A commemorative plaque at the former Tamamizuya optical shop location in Nagoya marks this achievement. This is a documented historical milestone in Japanese medical device history.

Menicon is described as the only manufacturer in the world dedicated to all areas of contact lens related businesses, including hyper-Dk rigid gas permeable lenses, silicone hydrogel lenses, and multipurpose lens care solutions. This full-spectrum capability is a verifiable claim based on the company's product portfolio.

The Miru 1day Menicon Flat Pack received FDA premarket notification clearance (510(k) number K102895), establishing it as a regulated Class II medical device in the United States. The Miru 1day UpSide line's silicone hydrogel material with Class 2 UV filtering is documented in the product specifications published by Menicon.

Menicon products have not appeared prominently in major consumer contact lens rankings such as the Forbes Vetted 2026 guide or ContactLens.com 2026 rankings, which focus on the major global brands. Menicon's recognition comes primarily from eye care professionals in the specialty and RGP lens segments rather than consumer-facing awards.

No major FDA recalls specific to Menicon branded products have been publicly documented in FDA recall databases as of August 2026. Menicon Singapore, the manufacturing entity for the Miru and ClearLab product lines, is registered with the FDA as an active manufacturing establishment and is subject to FDA inspection and quality system regulations.

As a manufacturer of Class II medical devices distributed in the United States, Menicon is subject to post-market surveillance requirements. Any manufacturing deviations would be managed through standard FDA recall procedures. The company's Japanese manufacturing operations are regulated by Japan's Pharmaceuticals and Medical Devices Agency.

No significant controversies, regulatory enforcement actions, or FDA Warning Letters specific to Menicon have been publicly documented in recent years. The company's private ownership and smaller scale relative to the major global manufacturers reduce its public scrutiny profile.

Menicon's 2007 acquisition of ClearLab intellectual property from 1-800 Contacts, and the separate sale of ClearLab manufacturing operations to Mi Gwang Contact Lens, is a matter of public record. This transaction has not generated controversy, and Menicon has operated the ClearLab brand and Singapore manufacturing independently since that time.